Immunocore/IMCR

$55.68

1.71%
-
1D1W1MYTD1YMAX

About Immunocore

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Ticker

IMCR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bahija Jallal

Employees

497

Headquarters

Abingdon, United Kingdom

Immunocore Metrics

BasicAdvanced
$2.66B
Market cap
-
P/E ratio
-$1.13
EPS
-
Beta
-
Dividend rate
$2.66B
$76.98
$42.21
494.82K
3.804
3.772
13.017
13.017
-173.4%
-9.84%
-15.62%
-12.51%
10.669
7.358
7.215
43.05%
1.61%
86.24%

What the Analysts think about Immunocore

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 15 analysts.
12,139.74% upside
High $7,341.78
Low $5,027.53
$55.68
Current price
$6,815.09
Average price target

Immunocore Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-22.13% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$249.4M
289.08%
Net income
$-55.2M
-2,500%
Profit margin
-22.13%
-718.16%

Immunocore Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 46.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-£28.17
-£23.34
£3.22
-$32.20
-
Expected
-£25.91
-£25.84
-£23.28
-$21.92
-£0.29
Surprise
8.72%
-9.67%
-113.83%
46.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Immunocore stock?

Immunocore (IMCR) has a market cap of $2.71B as of April 21, 2024.

What is the P/E ratio for Immunocore stock?

The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of April 21, 2024.

Does Immunocore stock pay dividends?

No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Immunocore dividend payment date?

Immunocore (IMCR) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunocore?

Immunocore (IMCR) does not currently have a Beta indicator.

What is the Immunocore stock price target?

The target price for Immunocore (IMCR) stock is $85.4, which is 53.38% above the current price of $55.68. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Immunocore stock

Buy or sell Immunocore stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing